Risk factors for chronic renal dysfunction in cardiac allograft recipients

Nephron

Volumn 84, Issue 1, 2000, Pages 21-28

  Esposito, C ^b   Semeraro, L ^b   Bellotti, N ^b   Fasoli, G ^b   Fornoni, A ^b   Rampino, T ^b   Klersy, C ^b   Campana, C ^b   Gavazzi, A ^b   Vigano M ^b   Dal Canton, Antonio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

Cardiac allograft recipients; Ciclosporin; Renal function, heart transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN; TRIACYLGLYCEROL; UREA; VERAPAMIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGRAFT; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART TRANSPLANTATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

EID: 0038500454     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045534     Document Type: Article

References (41)

1. Kahan BD: Cyclosporine. N Engl J Med 1989; 321:1725-1738.
2. Macoviak JA, Oyer PE, Stinson EB, Jamieson SW, Baldwin JC, Shumway NE: Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985; 17(suppl2):97-101.
3. Parameshwar J, Schofield P, Large S: Long-term complications of cardiac transplantation. Br Heart J 1995;74:341-342.
4. Goldstein DJ, Zuech N, Sehgal V, Weiberg AD, Drusin R, Cohen D: Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997;63:664-666.
5. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-1660.
6. Bertani T, Ferrazzi P, Schieppati A, Ruggenenti P, Gamba A, Parenzan L, Mecca G, Perico N, Imberti O, Remuzzi A, Remuzzi G: Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991;40:243-250.
7. Falkenhain ME, Cosio FG, Sedmark DD: Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996;62:364-370.
8. Woolfson RG, Neild GH: Cyclosporine nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 1997;12:2054-2056.
9. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 1984;311:699-705.
10. Gonwa TA, Mai ML, Pilcher JB, Johnson C, Pierson S, Capehart JE, Alivizatos PA: Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992;11:926-928.
11. Van Buren DH, Burke JF, Lewis RM: Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 1994; 4(suppl):17-22.
12. Griffiths MH, Crowe AV, Papadaki L, Banner NR, Yacoub MH, Thompson FD, Neild GH: Cyclosporine nephrotoxicity in heart and lung transplant patients. Q J Med 1996;89:751-763.
13. Chan C, Maurer J, Cardella C, Cattran D, Pei Y: A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997;63:1435-1440.
14. Agresti A: Model of Matched Pairs; in Categorical Data Analysis. New York, Wiley & Sons, 1990, pp 348-352.
15. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-387.
16. Schemper M, Stare J: Explained variation in survival analysis. Stat Med 1996;15:1999-2012.
17. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, Perlroth MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33: 590-600.
18. Goral S, Ynares C, Shyr Yu, Yeoh TK, Johnson HK: Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997;16:1106-1112.
19. Hartmann A, Andreassen AK, Holdaas H, Simonsen S, Geiran O, Berg KJ: Five years follow-up of renal glomerular and tubular functions in heart transplant recipients. J Heart Lung Transplant 1996;15:972-979.
20. Lloveras JJ, Durand D, Ader JL: Evolution of glomerular filtration rate and renal plasma flow in cyclosporine-treated heart transplant recipients over a one year period. Transplant Proc 1993;25:2226-2229.
21. McGiffin DC, Kirklin JK, McVay RF, Logic JR, Edwards ME, Diethelm AG: Conversion from cyclosporine to azathioprine following heart transplantation. J Heart Transplant 1986;5:99-104.
22. Greenberg A, Thompson ME, Griffith BJ, Hardesty RL, Kormos RL, El-Shahawy MA, Janosky JE, Puschett JB: Cyclosporine nephrotoxicity in cardiac allograft patients: A seven-year follow-up. Transplantation 1990;50:589-593.
23. Whiting DH: Acute and chronic nephropathy associated with immunosuppressive drugs. Curr Opin Nephrol Hypertens 1994;3:174-181.
24. Biglieri EG, Stockigt JR, Schambelan W: Adrenal mineralocorticoids causing hypertension. Am J Med 1972;52:623-632.
25. Keane WF: Lipids and kidney. Kidney Int 1994;46:910-920.
26. Maschio G, Oldrizzi L, Rugiu C, Loschiavo C: Serum lipids in patients with chronic renal failure on long-term, protein-restricted diets. Am J Med 1989;87:51N-54N.
27. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovich P, Attman PO: Apolipoprotein-B-containing lipoprotein and the progression of renal insufficiency. Nephron 1993;63:279-285.
28. Wheeler DC, Chana RS, Topley N, Petersen HM, Davies M, Williams JD: Oxidation of low density lipoproteins by mesangial cells may promote glomerular injury. Kidney Int 1994; 45:1628-1636.
29. Grone EF, Abbond HE, Hohne M, Welli AK, Grone HJ, Stucker D, Robenek H, Wieland E, Seidel D: Actions of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors. Am J Physiol 1992;263: F686-F696.
30. Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, Balletta M, Bellinghieri G, Conte G, Cianciaruso B, Dal Canton A: Effects of hypercholesterolemia on renal hemodynamics: Study in patients with nephrotic syndrome. Nephron 1996;73:430-435.
31. Creager MA, Cooke JP, Mendelsohn ME, Gallacher SI, Coleman SM, Loscalzo J, Dzau VJ: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-234.
32. Galle J, Wanner C: Impact of nitric oxide on renal hemodynamics and glomerulr function: Modulation by atherogenic lipoproteins?' Kidney Blood Press Res 1996;19:2-15.
33. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM Jr: Hyperlipidemia after heart transplantation: Report of a 6-year experience with treatment recommendations. J Am Coll Cardiol 1992;19: 1315-1321.
34. Kassirer JP, Harrington JT: Laboratory evaluation of renal function; in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney. Boston, Little, Brown, 1988, pp 393-441.
35. Dal Canton A, Fuiano G, Conte G, Terribile M, Sabbatini M, Cianciaruso B, Andreucci VE: Mechanism of increased plasma urea after diuretic therapy in uremic patients. Clin Sci 1985;68:255-261.
36. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.
37. Benigni A, Remuzzi G: Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 1996;16:151-159.
38. Brenner BM, Lawler EV, Mackenzie HS: The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int 1996;49:1774-1778.
39. Bluhm RE, Rodgers WH, Black DL, Wilkinson GR, Branch R: Cholestasis in transplant patients - what is the role of cyclosporine? Aliment Pharmacol Ther 1992;6:207-219.
40. Briner VA, Landmann J, Brunner FP, Thiel G: Cyclosporine A-induccd transient rise in plasma alkaline phosphatase in kidney transplant patients. Transpl Int 1993;6:99-107.
41. Bryer HP, Isserow JA, Armstrong EC, Mann GN, Rucinski B, Buchinsky FJ, Romero DF, Epstein S: Azathioprine alone is bone sparing and does not alter cyclosporine A-induced osteopenia in the rat. J Bone Miner Res 1995;10: 132-138.